Australia's Benitec to acquire US RNAi firm Tacere

15 October 2012

Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire the privately-held US RNA interference (RNAi) therapeutics company Tacere Therapeutics.

The transaction is expected to be completed on” favorable commercial terms” reflecting Benitec’s unique understanding of the assets and original licensing agreement covering the use of its ddRNAi technology.

Benitec Biopharma will acquire Tacere's extensive hepatitis C virus (HCV) program data and materials, as well as an advanced preclinical program for the eye disease macular degeneration, which also utilises the Company’s ddRNAi technology. At present, Tacere has a Phase I/II ready program in hepatitis C that utilizes Benitec’s novel gene silencing technology called DNA-directed RNA interference (ddRNAi).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK